Cogent Biosciences, Inc.
NASDAQ:COGTBiotechnology
+$0.88 today
- Market cap
- $4.83B
- Beta
- 0.35
- P/E (TTM)
- -6.6
- EPS (TTM)
- -$5.26
Volume 1.68M
Average 2.15M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Cogent Biosciences, Inc.
NASDAQ:COGT
Intrinsic Alpha fair value
Locked
Current Price
$27.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | N/A5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Incyte Corporation NASDAQ:INCY | $24.66B | $120.97 | Undervalued | 13.7 | +13.87% |
Tango Therapeutics, Inc. NASDAQ:TNGX | $4.32B | $25.50 | Not rated | -38.9 | +155.17% |
IDEAYA Biosciences, Inc. NASDAQ:IDYA | $3.08B | $31.83 | Not rated | -19.5 | -21.08% |
Arcus Biosciences, Inc. NYSE:RCUS | $2.51B | $17.43 | Not rated | -8.2 | -25.67% |
Maze Therapeutics, Inc. NASDAQ:MAZE | $1.88B | $34.33 | Not rated | -11.0 | -8.83% |
Nurix Therapeutics, Inc. NASDAQ:NRIX | $1.69B | $15.48 | Undervalued | -6.4 | -11.29% |
Syndax Pharmaceuticals, Inc. NASDAQ:SNDX | $850.77M | $9.45 | Not rated | -6.8 | -46.45% |
Kura Oncology, Inc. NASDAQ:KURA | $713.90M | $7.77 | Not rated | -2.9 | -33.06% |
ArriVent BioPharma, Inc. Common Stock NASDAQ:AVBP | $672.92M | $13.01 | Not rated | -9.8 | -43.87% |
Continue the stock analysis
Jump to another research area for this company.